The association between tocilizumab and the secondary bloodstream infection maybe nonsignificant in hospitalized patients with SARS-CoV-2 infection: A cohort study

Background: Immunomodulatory agents, such as tocilizumab (TCZ), exert promising effects against SARS-CoV-2 infection. However, growing evidence indicates that using TCZ may carry higher risks of secondary bloodstream infection (sBSI). This study determined whether TCZ is associated with an increased...

Повний опис

Бібліографічні деталі

Автори:	De-En Lu, Tsong-Yih Ou, Jyun-Wei Kang, Jie Ywi Ong, I-Ju Chen, Chih-Hsin Lee, Ming-Chia Lee
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2024-02-01
Серія:	Journal of Microbiology, Immunology and Infection
Предмети:	SARS-CoV-2 infection Secondary bloodstream infections Tocilizumab
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S1684118223002025
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!